CM
PVLA

CM Management’s Palvella Therapeutics PVLA Stock Holding History

CM Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-22,500
Closed -$373K – 66
2024
Q3 		$373K Buy
+22,500
New +$329K 0.3% 59
2024
Q2 		– Sell
-7,188
Closed -$105K – 73
2024
Q1 		$105K Sell
7,188
-2,187
-23% -$30.5K 0.09% 69
2023
Q4 		$137K Buy
9,375
+1,257
+15% +$23K 0.11% 72
2023
Q3 		$194K Buy
8,118
+1,243
+18% +$26.7K 0.21% 62
2023
Q2 		$91K Buy
+6,875
New +$417K 0.09% 72

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

CM Management's PVLA Position: Q4 2024 in Review

CM Management sold out of Palvella Therapeutics (PVLA) in Q4 2024, closing a stake of 22,500 shares — an estimated $373K sold.

CM Management first reported a position in PVLA in Q2 2023 and held it in 5 quarters. The position peaked at $373K in Q3 2024. 33 funds tracked by Wall St. Rank hold PVLA as of Q4 2024.

  • CM Management reported no remaining Palvella Therapeutics position as of Q4 2024 after selling out during the quarter.
  • CM Management sold 22,500 Palvella Therapeutics shares in Q4 2024, an estimated $373K.
  • CM Management first reported a position in Palvella Therapeutics in Q2 2023 and held it in 5 quarters.
  • CM Management's Palvella Therapeutics position peaked at $373K in Q3 2024.
  • 33 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q4 2024.

Based on CM Management's 13F filing for Q4 2024, filed 7 Feb 2025.